Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000029601
- Lead Sponsor
- Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pleural effusion, ascites or pericardial effusion requiring drainage 2)Other cancers 3)Symptomatic brain metastasis and meningitis 4)With severe complication 5)Interstitial pneumonia on CT 6)Severe drug allergy 7)Active autoimmune disease that has required systemic treatment 8)Dementia 9)Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Objective Response Rate Disease Control Rate Overall survival QO